Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational Phase 4 APeX-T study, designed to generate real-world data to inform physicians on the best individual approaches to support transition to ORLADEYO

Next Previous
Trial Profile

An observational Phase 4 APeX-T study, designed to generate real-world data to inform physicians on the best individual approaches to support transition to ORLADEYO

Status: Planning
Phase of Trial: Phase IV

Latest Information Update: 16 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berotralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Therapeutic Use
  • Acronyms APeX-T
  • Sponsors BioCryst Pharmaceuticals

Most Recent Events

  • 10 Jan 2025 According to a BioCryst Pharmaceuticals media release, operating expenses are forecasted at between $425 million and $435 million for the year includes additional commercial investment to support various activities including ongoing work on this transition study (APeX-T).
  • 10 Nov 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top